« Return to News | Clinical Intelligence

Singapore develops its first cancer drug

Thursday, March 17, 2011 01:27 PM

Singapore has developed its first cancer drug, SB-939, from two Singapore-based cancer institutes and a biotechnology company, S*BIO, according to Channel News Asia.   The Singapore National University Cancer Institute, the Cancer Institute of Singapore and S*BIO have collaborated for the phase I trials.

For over a year, the drug was administered orally to 30 cancer patients three times a week.  Of these, 24 tolerated the drug well and four showed better than expected tumor growth control.

Associate Professor Goh Boon Cher, senior consultant of the Singapore National University Cancer Institution, said, "the drug actually works by causing cancer cells to die preferentially over the normal cells. So there is some selective advantage to killing cancer."

"The main side effect was tiredness and some patients who had a lower platelet count. There were some insignificant abnormalities in electrocardiograms. In general, these side effects were tolerable, reversible and did not harm the patients,” said Goh.

Phase I assessed the safety and tolerability of the drug and served to set the dosage for the phase II trials.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.